nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ALB—Crohn's disease	0.519	1	CbGaD
Canagliflozin—ABCC2—Sulfasalazine—Crohn's disease	0.153	0.522	CbGbCtD
Canagliflozin—ALB—Prednisone—Crohn's disease	0.0765	0.26	CbGbCtD
Canagliflozin—ABCB1—Prednisone—Crohn's disease	0.04	0.136	CbGbCtD
Canagliflozin—CYP3A4—Prednisone—Crohn's disease	0.024	0.0815	CbGbCtD
Canagliflozin—ORM1—bile—Crohn's disease	0.0166	0.241	CbGeAlD
Canagliflozin—ABCC2—bile—Crohn's disease	0.0136	0.198	CbGeAlD
Canagliflozin—SLC5A1—epithelium—Crohn's disease	0.00719	0.104	CbGeAlD
Canagliflozin—SLC5A1—mammalian vulva—Crohn's disease	0.00624	0.0905	CbGeAlD
Canagliflozin—SLC5A1—digestive system—Crohn's disease	0.00547	0.0794	CbGeAlD
Canagliflozin—ORM1—gall bladder—Crohn's disease	0.00461	0.0668	CbGeAlD
Canagliflozin—ALB—gall bladder—Crohn's disease	0.00404	0.0586	CbGeAlD
Canagliflozin—UGT1A9—digestive system—Crohn's disease	0.00345	0.05	CbGeAlD
Canagliflozin—Rash generalised—Mesalazine—Crohn's disease	0.00306	0.0447	CcSEcCtD
Canagliflozin—Prurigo—Mesalazine—Crohn's disease	0.00282	0.0412	CcSEcCtD
Canagliflozin—SLC5A2—Hexose uptake—GCKR—Crohn's disease	0.00278	0.0559	CbGpPWpGaD
Canagliflozin—SLC5A1—Hexose uptake—GCKR—Crohn's disease	0.00278	0.0559	CbGpPWpGaD
Canagliflozin—Vulvovaginal candidiasis—Mesalazine—Crohn's disease	0.00247	0.0361	CcSEcCtD
Canagliflozin—Vulvovaginal mycotic infection—Mesalazine—Crohn's disease	0.00238	0.0348	CcSEcCtD
Canagliflozin—Micturition urgency—Mesalazine—Crohn's disease	0.00229	0.0335	CcSEcCtD
Canagliflozin—Blood potassium increased—Prednisone—Crohn's disease	0.00228	0.0333	CcSEcCtD
Canagliflozin—SLC5A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A4—Crohn's disease	0.00217	0.0437	CbGpPWpGaD
Canagliflozin—SLC5A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—Crohn's disease	0.00217	0.0437	CbGpPWpGaD
Canagliflozin—SLC5A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—Crohn's disease	0.00217	0.0437	CbGpPWpGaD
Canagliflozin—SLC5A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A4—Crohn's disease	0.00217	0.0437	CbGpPWpGaD
Canagliflozin—Rash erythematous—Mesalazine—Crohn's disease	0.0017	0.0248	CcSEcCtD
Canagliflozin—Rash pustular—Mesalazine—Crohn's disease	0.00163	0.0238	CcSEcCtD
Canagliflozin—Breast disorder—Mercaptopurine—Crohn's disease	0.00157	0.023	CcSEcCtD
Canagliflozin—ABCC2—digestive system—Crohn's disease	0.00149	0.0216	CbGeAlD
Canagliflozin—Pancreatitis—Mercaptopurine—Crohn's disease	0.00147	0.0215	CcSEcCtD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CPEB4—Crohn's disease	0.00145	0.0292	CbGpPWpGaD
Canagliflozin—SLC5A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—Crohn's disease	0.00135	0.0272	CbGpPWpGaD
Canagliflozin—SLC5A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—Crohn's disease	0.00135	0.0272	CbGpPWpGaD
Canagliflozin—Cystitis noninfective—Mesalazine—Crohn's disease	0.00127	0.0186	CcSEcCtD
Canagliflozin—Cystitis—Mesalazine—Crohn's disease	0.00126	0.0183	CcSEcCtD
Canagliflozin—Blood urea increased—Mesalazine—Crohn's disease	0.00123	0.0179	CcSEcCtD
Canagliflozin—Vaginal infection—Mesalazine—Crohn's disease	0.00123	0.0179	CcSEcCtD
Canagliflozin—Multiple fractures—Prednisone—Crohn's disease	0.00118	0.0173	CcSEcCtD
Canagliflozin—Fracture—Prednisone—Crohn's disease	0.00118	0.0173	CcSEcCtD
Canagliflozin—Bladder pain—Mesalazine—Crohn's disease	0.00118	0.0172	CcSEcCtD
Canagliflozin—Photosensitivity—Mesalazine—Crohn's disease	0.00107	0.0157	CcSEcCtD
Canagliflozin—Malnutrition—Mercaptopurine—Crohn's disease	0.00105	0.0153	CcSEcCtD
Canagliflozin—ORM1—lymph node—Crohn's disease	0.00104	0.015	CbGeAlD
Canagliflozin—Renal failure acute—Mesalazine—Crohn's disease	0.00102	0.0149	CcSEcCtD
Canagliflozin—Thirst—Mesalazine—Crohn's disease	0.000992	0.0145	CcSEcCtD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.000988	0.0199	CbGpPWpGaD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.000988	0.0199	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.000988	0.0199	CbGpPWpGaD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.000988	0.0199	CbGpPWpGaD
Canagliflozin—ALB—lymph node—Crohn's disease	0.000908	0.0132	CbGeAlD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.000885	0.0129	CcSEcCtD
Canagliflozin—Blood creatinine increased—Mesalazine—Crohn's disease	0.000884	0.0129	CcSEcCtD
Canagliflozin—Pancreatitis—Azathioprine—Crohn's disease	0.000878	0.0128	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Mesalazine—Crohn's disease	0.000862	0.0126	CcSEcCtD
Canagliflozin—Breast disorder—Mesalazine—Crohn's disease	0.000853	0.0125	CcSEcCtD
Canagliflozin—ABCC2—lymph node—Crohn's disease	0.000851	0.0123	CbGeAlD
Canagliflozin—Skin disorder—Mercaptopurine—Crohn's disease	0.00083	0.0121	CcSEcCtD
Canagliflozin—Pancreatitis—Mesalazine—Crohn's disease	0.0008	0.0117	CcSEcCtD
Canagliflozin—UGT2B4—Metapathway biotransformation—GPX4—Crohn's disease	0.000764	0.0154	CbGpPWpGaD
Canagliflozin—CYP3A4—digestive system—Crohn's disease	0.000757	0.011	CbGeAlD
Canagliflozin—Pollakiuria—Mesalazine—Crohn's disease	0.000754	0.011	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Mesalazine—Crohn's disease	0.000745	0.0109	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000738	0.0108	CcSEcCtD
Canagliflozin—Urinary tract infection—Mesalazine—Crohn's disease	0.000707	0.0103	CcSEcCtD
Canagliflozin—ABCB1—epithelium—Crohn's disease	0.000704	0.0102	CbGeAlD
Canagliflozin—SLC5A1—Carbohydrate metabolism—GCKR—Crohn's disease	0.000698	0.014	CbGpPWpGaD
Canagliflozin—SLC5A2—Carbohydrate metabolism—GCKR—Crohn's disease	0.000698	0.014	CbGpPWpGaD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.000696	0.014	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.000696	0.014	CbGpPWpGaD
Canagliflozin—Urinary tract disorder—Mesalazine—Crohn's disease	0.000645	0.00942	CcSEcCtD
Canagliflozin—Urethral disorder—Mesalazine—Crohn's disease	0.00064	0.00935	CcSEcCtD
Canagliflozin—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00063	0.0092	CcSEcCtD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.000615	0.0124	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.000615	0.0124	CbGpPWpGaD
Canagliflozin—ABCB1—mammalian vulva—Crohn's disease	0.000611	0.00886	CbGeAlD
Canagliflozin—Angiopathy—Mesalazine—Crohn's disease	0.000592	0.00866	CcSEcCtD
Canagliflozin—Diabetes mellitus—Prednisone—Crohn's disease	0.000574	0.00839	CcSEcCtD
Canagliflozin—Erythema—Mesalazine—Crohn's disease	0.000568	0.00831	CcSEcCtD
Canagliflozin—ABCB1—lymphoid tissue—Crohn's disease	0.000542	0.00786	CbGeAlD
Canagliflozin—Rash—Mercaptopurine—Crohn's disease	0.000539	0.00788	CcSEcCtD
Canagliflozin—Dermatitis—Mercaptopurine—Crohn's disease	0.000538	0.00787	CcSEcCtD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—Crohn's disease	0.000537	0.0108	CbGpPWpGaD
Canagliflozin—ABCB1—digestive system—Crohn's disease	0.000536	0.00777	CbGeAlD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000528	0.00771	CcSEcCtD
Canagliflozin—Angioedema—Mesalazine—Crohn's disease	0.000519	0.00759	CcSEcCtD
Canagliflozin—Syncope—Mesalazine—Crohn's disease	0.00051	0.00745	CcSEcCtD
Canagliflozin—Nausea—Mercaptopurine—Crohn's disease	0.000508	0.00742	CcSEcCtD
Canagliflozin—Infection—Azathioprine—Crohn's disease	0.000506	0.00739	CcSEcCtD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000502	0.0101	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000502	0.0101	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000502	0.0101	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000502	0.0101	CbGpPWpGaD
Canagliflozin—Loss of consciousness—Mesalazine—Crohn's disease	0.0005	0.0073	CcSEcCtD
Canagliflozin—Skin disorder—Azathioprine—Crohn's disease	0.000495	0.00723	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000481	0.00702	CcSEcCtD
Canagliflozin—Hypotension—Azathioprine—Crohn's disease	0.000476	0.00695	CcSEcCtD
Canagliflozin—Dry mouth—Mesalazine—Crohn's disease	0.000473	0.00692	CcSEcCtD
Canagliflozin—Infection—Mesalazine—Crohn's disease	0.000461	0.00674	CcSEcCtD
Canagliflozin—Shock—Mesalazine—Crohn's disease	0.000456	0.00667	CcSEcCtD
Canagliflozin—Nervous system disorder—Mesalazine—Crohn's disease	0.000455	0.00665	CcSEcCtD
Canagliflozin—Skin disorder—Mesalazine—Crohn's disease	0.000451	0.00659	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.00044	0.00643	CcSEcCtD
Canagliflozin—UGT1A9—PPARA activates gene expression—FADS1—Crohn's disease	0.000438	0.0088	CbGpPWpGaD
Canagliflozin—Hypotension—Mesalazine—Crohn's disease	0.000433	0.00633	CcSEcCtD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—FADS1—Crohn's disease	0.000428	0.00861	CbGpPWpGaD
Canagliflozin—Pancreatitis—Prednisone—Crohn's disease	0.000423	0.00618	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000416	0.00609	CcSEcCtD
Canagliflozin—Abdominal pain—Azathioprine—Crohn's disease	0.000403	0.00588	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.0004	0.00585	CcSEcCtD
Canagliflozin—Fatigue—Mesalazine—Crohn's disease	0.0004	0.00584	CcSEcCtD
Canagliflozin—Constipation—Mesalazine—Crohn's disease	0.000397	0.0058	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000379	0.00554	CcSEcCtD
Canagliflozin—Hypersensitivity—Azathioprine—Crohn's disease	0.000375	0.00548	CcSEcCtD
Canagliflozin—Urticaria—Mesalazine—Crohn's disease	0.000369	0.00539	CcSEcCtD
Canagliflozin—Abdominal pain—Mesalazine—Crohn's disease	0.000367	0.00536	CcSEcCtD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000354	0.00711	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000354	0.00711	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Mesalazine—Crohn's disease	0.000342	0.00499	CcSEcCtD
Canagliflozin—Dizziness—Azathioprine—Crohn's disease	0.000337	0.00492	CcSEcCtD
Canagliflozin—Asthenia—Mesalazine—Crohn's disease	0.000333	0.00486	CcSEcCtD
Canagliflozin—Pruritus—Mesalazine—Crohn's disease	0.000328	0.0048	CcSEcCtD
Canagliflozin—ABCB1—Allograft Rejection—LRRK2—Crohn's disease	0.000327	0.00658	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—GPX4—Crohn's disease	0.000323	0.00649	CbGpPWpGaD
Canagliflozin—Rash—Azathioprine—Crohn's disease	0.000321	0.00469	CcSEcCtD
Canagliflozin—Dermatitis—Azathioprine—Crohn's disease	0.000321	0.00469	CcSEcCtD
Canagliflozin—Angiopathy—Prednisone—Crohn's disease	0.000313	0.00458	CcSEcCtD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.000313	0.00628	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.000313	0.00628	CbGpPWpGaD
Canagliflozin—Dizziness—Mesalazine—Crohn's disease	0.000307	0.00448	CcSEcCtD
Canagliflozin—ABCB1—lymph node—Crohn's disease	0.000306	0.00444	CbGeAlD
Canagliflozin—ALB—Vitamin B12 Metabolism—MPO—Crohn's disease	0.000303	0.00608	CbGpPWpGaD
Canagliflozin—Nausea—Azathioprine—Crohn's disease	0.000303	0.00442	CcSEcCtD
Canagliflozin—Malnutrition—Prednisone—Crohn's disease	0.000301	0.0044	CcSEcCtD
Canagliflozin—Erythema—Prednisone—Crohn's disease	0.000301	0.0044	CcSEcCtD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—FADS1—Crohn's disease	0.000295	0.00593	CbGpPWpGaD
Canagliflozin—Rash—Mesalazine—Crohn's disease	0.000292	0.00427	CcSEcCtD
Canagliflozin—Dermatitis—Mesalazine—Crohn's disease	0.000292	0.00427	CcSEcCtD
Canagliflozin—SLC5A1—Disease—RSPO3—Crohn's disease	0.000289	0.0058	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—RSPO3—Crohn's disease	0.000289	0.0058	CbGpPWpGaD
Canagliflozin—UGT1A9—Metapathway biotransformation—GPX4—Crohn's disease	0.000283	0.00568	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—F5—Crohn's disease	0.00028	0.00563	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PLA2G4F—Crohn's disease	0.000277	0.00556	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PLA2G4F—Crohn's disease	0.000277	0.00556	CbGpPWpGaD
Canagliflozin—Nausea—Mesalazine—Crohn's disease	0.000276	0.00403	CcSEcCtD
Canagliflozin—Angioedema—Prednisone—Crohn's disease	0.000275	0.00402	CcSEcCtD
Canagliflozin—SLC5A1—Disease—SEL1L—Crohn's disease	0.000274	0.0055	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—SEL1L—Crohn's disease	0.000274	0.0055	CbGpPWpGaD
Canagliflozin—Syncope—Prednisone—Crohn's disease	0.00027	0.00394	CcSEcCtD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—F5—Crohn's disease	0.000267	0.00537	CbGpPWpGaD
Canagliflozin—Loss of consciousness—Prednisone—Crohn's disease	0.000264	0.00386	CcSEcCtD
Canagliflozin—Convulsion—Prednisone—Crohn's disease	0.000261	0.00381	CcSEcCtD
Canagliflozin—ALB—Selenium Micronutrient Network—GPX4—Crohn's disease	0.000257	0.00516	CbGpPWpGaD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000254	0.00372	CcSEcCtD
Canagliflozin—ALB—Folate Metabolism—MPO—Crohn's disease	0.000246	0.00495	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—LTF—Crohn's disease	0.000245	0.00493	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—LTF—Crohn's disease	0.000245	0.00493	CbGpPWpGaD
Canagliflozin—Infection—Prednisone—Crohn's disease	0.000244	0.00356	CcSEcCtD
Canagliflozin—Shock—Prednisone—Crohn's disease	0.000241	0.00353	CcSEcCtD
Canagliflozin—Nervous system disorder—Prednisone—Crohn's disease	0.000241	0.00352	CcSEcCtD
Canagliflozin—Skin disorder—Prednisone—Crohn's disease	0.000238	0.00348	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—MTMR3—Crohn's disease	0.000235	0.00473	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—MTMR3—Crohn's disease	0.000235	0.00473	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—Crohn's disease	0.000231	0.00464	CbGpPWpGaD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—ALB—Crohn's disease	0.000222	0.00445	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—ALB—Crohn's disease	0.000222	0.00445	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PLA2G4F—Crohn's disease	0.000214	0.00429	CbGpPWpGaD
Canagliflozin—Fatigue—Prednisone—Crohn's disease	0.000212	0.00309	CcSEcCtD
Canagliflozin—Constipation—Prednisone—Crohn's disease	0.00021	0.00307	CcSEcCtD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL1B—Crohn's disease	0.000206	0.00414	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Prednisone—Crohn's disease	0.000201	0.00293	CcSEcCtD
Canagliflozin—SLC5A1—Disease—GCKR—Crohn's disease	0.000198	0.00398	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—GCKR—Crohn's disease	0.000198	0.00398	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—MPO—Crohn's disease	0.000196	0.00393	CbGpPWpGaD
Canagliflozin—Urticaria—Prednisone—Crohn's disease	0.000195	0.00285	CcSEcCtD
Canagliflozin—Abdominal pain—Prednisone—Crohn's disease	0.000194	0.00284	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—FADS1—Crohn's disease	0.000183	0.00368	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—FADS1—Crohn's disease	0.000183	0.00368	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—MTMR3—Crohn's disease	0.000182	0.00365	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MST1—Crohn's disease	0.000181	0.00364	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Prednisone—Crohn's disease	0.000181	0.00264	CcSEcCtD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000177	0.00357	CbGpPWpGaD
Canagliflozin—Asthenia—Prednisone—Crohn's disease	0.000176	0.00257	CcSEcCtD
Canagliflozin—SLC5A1—Disease—SLC11A1—Crohn's disease	0.000175	0.00351	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—SLC11A1—Crohn's disease	0.000175	0.00351	CbGpPWpGaD
Canagliflozin—Pruritus—Prednisone—Crohn's disease	0.000174	0.00254	CcSEcCtD
Canagliflozin—ABCB1—Allograft Rejection—IL17A—Crohn's disease	0.000172	0.00346	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GPX4—Crohn's disease	0.000172	0.00345	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GPX4—Crohn's disease	0.000172	0.00345	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GCKR—Crohn's disease	0.000166	0.00333	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GCKR—Crohn's disease	0.000166	0.00333	CbGpPWpGaD
Canagliflozin—Dizziness—Prednisone—Crohn's disease	0.000162	0.00237	CcSEcCtD
Canagliflozin—ABCB1—Allograft Rejection—IL12B—Crohn's disease	0.00016	0.00321	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—CRP—Crohn's disease	0.000159	0.0032	CbGpPWpGaD
Canagliflozin—Rash—Prednisone—Crohn's disease	0.000155	0.00226	CcSEcCtD
Canagliflozin—Dermatitis—Prednisone—Crohn's disease	0.000155	0.00226	CcSEcCtD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000151	0.00303	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—RBX1—Crohn's disease	0.00015	0.00301	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HSPA1B—Crohn's disease	0.00015	0.00301	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—RBX1—Crohn's disease	0.00015	0.00301	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HSPA1B—Crohn's disease	0.00015	0.00301	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—Crohn's disease	0.000149	0.003	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.000148	0.00297	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.000148	0.00297	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—ICAM1—Crohn's disease	0.000146	0.00294	CbGpPWpGaD
Canagliflozin—Nausea—Prednisone—Crohn's disease	0.000146	0.00213	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—FADS1—Crohn's disease	0.000141	0.00284	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.00014	0.00281	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.00014	0.00281	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GPX4—Crohn's disease	0.000132	0.00266	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—UBE2D1—Crohn's disease	0.000131	0.00264	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—UBE2D1—Crohn's disease	0.000131	0.00264	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—SMAD3—Crohn's disease	0.00013	0.00261	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—CRP—Crohn's disease	0.00013	0.0026	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GCKR—Crohn's disease	0.000128	0.00257	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—F5—Crohn's disease	0.000124	0.0025	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—ICAM1—Crohn's disease	0.000119	0.00239	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000118	0.00236	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL10—Crohn's disease	0.000117	0.00235	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—ALB—Crohn's disease	0.000113	0.00226	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—ALB—Crohn's disease	0.000113	0.00226	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IFNG—Crohn's disease	0.000111	0.00224	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.00011	0.00221	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL2RA—Crohn's disease	0.000104	0.00209	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.000104	0.00209	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—CRP—Crohn's disease	0.000103	0.00207	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IL1B—Crohn's disease	9.93e-05	0.002	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—GCKR—Crohn's disease	9.86e-05	0.00198	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—ICAM1—Crohn's disease	9.46e-05	0.0019	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—SMAD3—Crohn's disease	9.41e-05	0.00189	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—SMAD3—Crohn's disease	9.41e-05	0.00189	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	9.29e-05	0.00187	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	9.21e-05	0.00185	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IFNG—Crohn's disease	9.06e-05	0.00182	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	8.72e-05	0.00175	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL1B—Crohn's disease	8.08e-05	0.00162	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GPX4—Crohn's disease	7.99e-05	0.00161	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PLA2G4F—Crohn's disease	7.9e-05	0.00159	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	7.9e-05	0.00159	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	7.51e-05	0.00151	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	7.51e-05	0.00151	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL3—Crohn's disease	7.45e-05	0.0015	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	7.34e-05	0.00147	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—RASGRP1—Crohn's disease	7.21e-05	0.00145	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—TNF—Crohn's disease	7.21e-05	0.00145	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IFNG—Crohn's disease	7.2e-05	0.00145	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—PTGS2—Crohn's disease	6.9e-05	0.00139	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IFNG—Crohn's disease	6.87e-05	0.00138	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—MTMR3—Crohn's disease	6.72e-05	0.00135	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	6.58e-05	0.00132	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	6.58e-05	0.00132	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IL1B—Crohn's disease	6.42e-05	0.00129	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—F5—Crohn's disease	6.41e-05	0.00129	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CXCL8—Crohn's disease	6.39e-05	0.00128	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	6.15e-05	0.00124	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TYK2—Crohn's disease	6.14e-05	0.00123	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TYK2—Crohn's disease	6.14e-05	0.00123	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL1B—Crohn's disease	6.13e-05	0.00123	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TNF—Crohn's disease	5.86e-05	0.00118	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—JAK2—Crohn's disease	5.85e-05	0.00118	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—JAK2—Crohn's disease	5.85e-05	0.00118	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IL6—Crohn's disease	5.82e-05	0.00117	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	5.76e-05	0.00116	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CD4—Crohn's disease	5.55e-05	0.00112	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CD4—Crohn's disease	5.55e-05	0.00112	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTGS2—Crohn's disease	5.51e-05	0.00111	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTGS2—Crohn's disease	5.51e-05	0.00111	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—GCKR—Crohn's disease	5.29e-05	0.00106	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ALB—Crohn's disease	5.27e-05	0.00106	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ALB—Crohn's disease	5.27e-05	0.00106	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—FADS1—Crohn's disease	5.24e-05	0.00105	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	5.22e-05	0.00105	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GPX4—Crohn's disease	4.9e-05	0.000985	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GCKR—Crohn's disease	4.73e-05	0.000951	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL6—Crohn's disease	4.73e-05	0.000951	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	4.68e-05	0.00094	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—TNF—Crohn's disease	4.66e-05	0.000936	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—GCKR—Crohn's disease	4.64e-05	0.000932	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTGS2—Crohn's disease	4.61e-05	0.000927	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTGS2—Crohn's disease	4.61e-05	0.000927	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TNF—Crohn's disease	4.45e-05	0.000894	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—STAT3—Crohn's disease	4.3e-05	0.000863	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—STAT3—Crohn's disease	4.3e-05	0.000863	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PLA2G4F—Crohn's disease	4.14e-05	0.000832	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	4.1e-05	0.000824	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ALB—Crohn's disease	4.07e-05	0.000818	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ITGA4—Crohn's disease	3.94e-05	0.000792	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL3—Crohn's disease	3.84e-05	0.000772	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IL6—Crohn's disease	3.76e-05	0.000755	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—RASGRP1—Crohn's disease	3.72e-05	0.000747	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PLA2G4F—Crohn's disease	3.63e-05	0.000729	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTGS2—Crohn's disease	3.56e-05	0.000716	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MTMR3—Crohn's disease	3.52e-05	0.000707	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	3.51e-05	0.000705	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	3.38e-05	0.00068	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	3.25e-05	0.000653	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ALB—Crohn's disease	3.14e-05	0.000631	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTMR3—Crohn's disease	3.08e-05	0.000619	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IL6—Crohn's disease	3e-05	0.000603	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IL6—Crohn's disease	3e-05	0.000603	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	2.96e-05	0.000595	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—FADS1—Crohn's disease	2.74e-05	0.000551	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2RA—Crohn's disease	2.69e-05	0.000541	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GPX4—Crohn's disease	2.57e-05	0.000516	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GCKR—Crohn's disease	2.48e-05	0.000498	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—FADS1—Crohn's disease	2.4e-05	0.000483	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPX4—Crohn's disease	2.25e-05	0.000452	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	2.23e-05	0.000449	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	2.2e-05	0.000441	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GCKR—Crohn's disease	2.17e-05	0.000436	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTMR3—Crohn's disease	1.9e-05	0.000382	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—JAK2—Crohn's disease	1.81e-05	0.000364	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.55e-05	0.000311	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALB—Crohn's disease	1.51e-05	0.000303	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—FADS1—Crohn's disease	1.48e-05	0.000297	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	1.48e-05	0.000297	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPX4—Crohn's disease	1.39e-05	0.000278	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GCKR—Crohn's disease	1.34e-05	0.000269	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—Crohn's disease	1.32e-05	0.000265	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALB—Crohn's disease	6.91e-06	0.000139	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—Crohn's disease	6.9e-06	0.000139	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—Crohn's disease	6.05e-06	0.000122	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALB—Crohn's disease	4.26e-06	8.56e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—Crohn's disease	3.73e-06	7.49e-05	CbGpPWpGaD
